Status:
COMPLETED
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Lead Sponsor:
Traws Pharma, Inc.
Collaborating Sponsors:
The Leukemia and Lymphoma Society
Conditions:
Myelodysplastic Syndromes
MDS
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to compare overall survival (OS) in patients receiving ON 01910.Na + best supportive care (BSC) to OS of patients receiving BSC in a population of patients with ...
Detailed Description
This is a Phase III open-label, randomized, controlled, multicenter study (up to 50 centers). Approximately 270 patients with MDS classified as RAEB-1 and RAEB-2 using the WHO classification and as RA...
Eligibility Criteria
Inclusion
- MDS diagnosis confirmed within 6 weeks prior to entry according to WHO or FAB classification
- MDS classified as follows, according to WHO and FAB classification:
- RAEB-1 (5% - 9% BM blasts)
- RAEB-2 (10% - 19% BM blasts)
- CMML (10% - 20% BM blasts) and WBC \< 13,000/μL
- RAEB-t (20% - 30% BM blasts), with following criteria:
- o WBC \< 25 x 10E9/L at entry
- o Stable WBC at least 4 weeks prior to entry and not requiring intervention for WBC control with hydroxyurea, chemotherapy, or leukopheresis.
- At least one cytopenia (ANC \< 1800/µL or platelet count \< 100,000/µL or hemoglobin \<10 g/dL)
- Progression according to 2006 International Working Group (IWG) criteria any time after start of azacitidine or decitabine during past 2 years; or failure to achieve complete or partial response or hematological improvement (according to 2006 IWG) after at least six 4-week cycles of azacitidine or four 6-week cycles of decitabine during past 2 years; or relapse after initial complete or partial response or hematological improvement (according to 2006 IWG criteria) observed after at least six 4-week cycles of azacitidine or four 6-week cycles of decitabine during past 2 years; or, intolerance to azacitidine or decitabine defined by drug-related ≥Grade 3 liver or renal toxicity leading to discontinuation during the past 2 years.
- Did not respond to, relapsed after, not eligible for, or opted not to do bone marrow transplantation
- Off other MDS treatments for at least 4 weeks; Filgrastim (G-CSF) and erythropoietin allowed before and during the study as clinically indicated.
- No need for induction chemotherapy
- ECOG status 0, 1 or 2
- Willing to adhere to protocol prohibitions and restrictions
- Patient (or a legally authorized representative) must sign informed consent form to indicate patient's understanding study's purpose and procedures and willingness to participate
Exclusion
- Anemia due to factors other than MDS (including hemolysis or gastrointestinal bleeding) unless stabilized for 1 week after RBC transfusion.
- Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- Active infection not adequately responding to appropriate therapy
- Total bilirubin ≥1.5 mg/dL not related to hemolysis or Gilbert's disease.
- Alanine transaminase (ALT)/aspartate transaminase (AST) ≥2.5 x upper limit of normal (ULN)
- Serum creatinine ≥2.0 mg/dL
- Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of \<130 mEq/L)
- Pregnant or lactating females
- Patients unwilling to follow strict contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives \[birth control pills\], contraceptive injections, intrauterine device, double-barrier method \[spermicidal jelly or foam with condoms or diaphragm\], contraceptive patch, or surgical sterilization) before entry and throughout the study
- Females with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin pregnancy test at screening
- Major surgery without full recovery or major surgery within 3 weeks of ON 01910.Na treatment start
- Uncontrolled hypertension (defined as systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg)
- New onset seizures (within 3 months prior to first dose of ON 01910.Na) or poorly controlled seizures
- Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy
- Prior treatment with low-dose cytarabine during past 2 years Investigational therapy within 4 weeks of starting ON 01910.Na
- Psychiatric illness or social situation that limits the patient's ability to tolerate and/or comply with study requirements
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 3 2018
Estimated Enrollment :
299 Patients enrolled
Trial Details
Trial ID
NCT01241500
Start Date
November 1 2010
End Date
October 3 2018
Last Update
June 30 2020
Active Locations (87)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia G. Piper Cancer Center
Scottsdale, Arizona, United States, 85258
2
University of California San Diego Moores Cancer Center
La Jolla, California, United States, 92093
3
Stanford Cancer Center
Stanford, California, United States, 94305
4
Yale Cancer Center
New Haven, Connecticut, United States, 06520